Query 1: Given the following hypothesis (and rationale) about the pathogenesis of celiac disease, find scientific evidence to support and/or refute this hypothesis.
Format your response with the following headings: **Supporting evidence**: <supporting info>, **Countering evidence**: <refutation>, **Conclusion**: <conclusion>

Hypothesis: Hypothesis: : Viral infections trigger epigenetic modifications in intestinal epithelial cells, altering tight junction protein expression and creating a permeable barrier that facilitates gluten peptide translocation and immune activation in genetically susceptible individuals.
Rationale: : Recent evidence suggests viral infections can induce lasting epigenetic changes. Rotavirus and other enteric viruses are associated with celiac disease onset, potentially through chromatin remodeling affecting barrier function genes.
Answer 1: Supporting evidence:
The provided texts establish a strong association between various viral infections (including rotavirus, enteroviruses, reoviruses, adenoviruses, and herpes viruses) and the development or increased risk of celiac disease (CD), particularly in genetically predisposed individuals (HLA-DQ2/DQ8 carriers) (chuda2017virusesinthe pages 41-44, cohen2023virusesandceliac pages 5-6, barone2021acumulativeeffect pages 1-2, sanchez2021contributionofinfectious pages 4-5). Viral infections are implicated in disrupting oral tolerance to gluten and promoting a pro-inflammatory Th1 immune response (cohen2023virusesandceliac pages 5-6, barone2022pivotalroleof pages 1-2, brown2018definingreovirusstrainspecific pages 36-42). Several sources indicate that viral infections can lead to intestinal inflammation and alter intestinal barrier function, increasing permeability (cohen2023virusesandceliac pages 5-6, barone2021acumulativeeffect pages 2-4, sanchez2021contributionofinfectious pages 4-5). For instance, anti-rotavirus VP7 antibodies have been shown to affect gene expression related to epithelial apoptosis, inflammation, and barrier integrity (cohen2023virusesandceliac pages 5-6). Increased intestinal permeability is a recognized critical factor in CD pathogenesis, facilitating the translocation of gluten peptides across the epithelial barrier, which then triggers an immune response in susceptible individuals (chuda2017virusesinthe pages 41-44, barone2021acumulativeeffect pages 1-2, barone2022pivotalroleof pages 7-8, rossi2023interactionbetweengut pages 1-2). Some texts note that viral ligands can activate innate immune pathways (e.g., TLRs, IFN-α), contributing to inflammation and potentially barrier dysfunction (barone2021acumulativeeffect pages 2-4, cohen2023virusesandceliac pages 1-2, rossi2023interactionbetweengut pages 2-3). The necessity of a combination of viral infection, gluten exposure, inflammatory cytokines, and genetic susceptibility is also highlighted (cohen2023virusesandceliac pages 5-6).

Countering evidence:
A consistent finding across nearly all provided excerpts is the lack of direct scientific evidence supporting the specific hypothesis that viral infections trigger epigenetic modifications (such as DNA methylation or histone modifications) in intestinal epithelial cells, which in turn directly alter tight junction protein expression leading to increased permeability. Multiple sources explicitly state that such viral-induced epigenetic mechanisms affecting tight junctions are not detailed, not explicitly covered, remain unelaborated, or lack direct evidence in the reviewed literature (chuda2017virusesinthe pages 41-44, cohen2023virusesandceliac pages 5-6, barone2021acumulativeeffect pages 1-2, barone2021acumulativeeffect pages 2-4, barone2022pivotalroleof pages 1-2, barone2022pivotalroleof pages 11-12, brown2018definingreovirusstrainspecific pages 28-36, chuda2017virusesinthe pages 18-21, cohen2023virusesandceliac pages 1-2, gudeta2023aspectsofimmunogenetics pages 70-73, rossi2023interactionbetweengut pages 1-2, sanchez2021contributionofinfectious pages 4-5). While the texts acknowledge that viral infections can lead to inflammation and barrier dysfunction, the specific role of virally-induced epigenetic changes in modulating tight junction proteins is not substantiated by the provided information. The enzyme ADAR1, involved in RNA editing and dysregulated in CD, is mentioned in one source as possibly linked to viral RNA sensing, but this does not directly confirm epigenetic modifications of DNA or histones affecting tight junctions (cohen2023virusesandceliac pages 1-2).

Conclusion:
The provided scientific context strongly supports the association between viral infections and an increased risk of celiac disease, particularly in genetically susceptible individuals. Viruses are implicated in breaking oral tolerance to gluten, inducing intestinal inflammation, and increasing intestinal permeability, which facilitates gluten peptide translocation and subsequent immune activation. However, the specific hypothesized mechanism—that viral infections trigger epigenetic modifications (like DNA methylation or histone changes) in intestinal epithelial cells which then directly alter tight junction protein expression—is not directly supported by evidence within these texts. The excerpts consistently state that direct evidence for such viral-induced epigenetic regulation of tight junctions in the context of CD pathogenesis is currently lacking or unaddressed in the cited literature. While the overall hypothesis is plausible in its components (viruses trigger CD, permeability is key), the direct link through viral-induced epigenetic changes affecting tight junction proteins in intestinal epithelial cells remains speculative based on the supplied information.
References 1:
1. (chuda2017virusesinthe pages 41-44): K Chudá. Viruses in the pathogenesis of coeliac disease. Unknown journal, 2017.

2. (cohen2023virusesandceliac pages 5-6): Ramon Cohen, Keren Mahlab-Guri, Malka Atali, and Daniel Elbirt. Viruses and celiac disease: what do we know ? Clinical and Experimental Medicine, 23:2931-2939, Apr 2023. URL: https://doi.org/10.1007/s10238-023-01070-9, doi:10.1007/s10238-023-01070-9. This article has 8 citations and is from a peer-reviewed journal.

3. (barone2021acumulativeeffect pages 1-2): Maria Vittoria Barone and Salvatore Auricchio. A cumulative effect of food and viruses to trigger celiac disease (cd): a commentary on the recent literature. International Journal of Molecular Sciences, 22:2027, Feb 2021. URL: https://doi.org/10.3390/ijms22042027, doi:10.3390/ijms22042027. This article has 12 citations and is from a peer-reviewed journal.

4. (barone2021acumulativeeffect pages 2-4): Maria Vittoria Barone and Salvatore Auricchio. A cumulative effect of food and viruses to trigger celiac disease (cd): a commentary on the recent literature. International Journal of Molecular Sciences, 22:2027, Feb 2021. URL: https://doi.org/10.3390/ijms22042027, doi:10.3390/ijms22042027. This article has 12 citations and is from a peer-reviewed journal.

5. (barone2022pivotalroleof pages 1-2): Maria Vittoria Barone, Renata Auricchio, Merlin Nanayakkara, Luigi Greco, Riccardo Troncone, and Salvatore Auricchio. Pivotal role of inflammation in celiac disease. International Journal of Molecular Sciences, 23:7177, Jun 2022. URL: https://doi.org/10.3390/ijms23137177, doi:10.3390/ijms23137177. This article has 36 citations and is from a peer-reviewed journal.

6. (barone2022pivotalroleof pages 11-12): Maria Vittoria Barone, Renata Auricchio, Merlin Nanayakkara, Luigi Greco, Riccardo Troncone, and Salvatore Auricchio. Pivotal role of inflammation in celiac disease. International Journal of Molecular Sciences, 23:7177, Jun 2022. URL: https://doi.org/10.3390/ijms23137177, doi:10.3390/ijms23137177. This article has 36 citations and is from a peer-reviewed journal.

7. (barone2022pivotalroleof pages 7-8): Maria Vittoria Barone, Renata Auricchio, Merlin Nanayakkara, Luigi Greco, Riccardo Troncone, and Salvatore Auricchio. Pivotal role of inflammation in celiac disease. International Journal of Molecular Sciences, 23:7177, Jun 2022. URL: https://doi.org/10.3390/ijms23137177, doi:10.3390/ijms23137177. This article has 36 citations and is from a peer-reviewed journal.

8. (brown2018definingreovirusstrainspecific pages 28-36): JJ Brown. Defining reovirus strain-specific differences that trigger inflammation to dietary antigen in the development of celiac disease. Unknown journal, 2018.

9. (brown2018definingreovirusstrainspecific pages 36-42): JJ Brown. Defining reovirus strain-specific differences that trigger inflammation to dietary antigen in the development of celiac disease. Unknown journal, 2018.

10. (chuda2017virusesinthe pages 18-21): K Chudá. Viruses in the pathogenesis of coeliac disease. Unknown journal, 2017.

11. (cohen2023virusesandceliac pages 1-2): Ramon Cohen, Keren Mahlab-Guri, Malka Atali, and Daniel Elbirt. Viruses and celiac disease: what do we know ? Clinical and Experimental Medicine, 23:2931-2939, Apr 2023. URL: https://doi.org/10.1007/s10238-023-01070-9, doi:10.1007/s10238-023-01070-9. This article has 8 citations and is from a peer-reviewed journal.

12. (gudeta2023aspectsofimmunogenetics pages 70-73): AN Gudeta. Aspects of immunogenetics, infections, and nutrition on the risk of celiac disease autoimmunity in an ethiopian pediatric birth cohort. Unknown journal, 2023.

13. (rossi2023interactionbetweengut pages 1-2): Roberta Elisa Rossi, Giulia Dispinzieri, Alessandra Elvevi, and Sara Massironi. Interaction between gut microbiota and celiac disease: from pathogenesis to treatment. Cells, 12:823, Mar 2023. URL: https://doi.org/10.3390/cells12060823, doi:10.3390/cells12060823. This article has 27 citations and is from a peer-reviewed journal.

14. (rossi2023interactionbetweengut pages 2-3): Roberta Elisa Rossi, Giulia Dispinzieri, Alessandra Elvevi, and Sara Massironi. Interaction between gut microbiota and celiac disease: from pathogenesis to treatment. Cells, 12:823, Mar 2023. URL: https://doi.org/10.3390/cells12060823, doi:10.3390/cells12060823. This article has 27 citations and is from a peer-reviewed journal.

15. (sanchez2021contributionofinfectious pages 4-5): Daniel Sánchez, Iva Hoffmanová, Adéla Szczepanková, Věra Hábová, and Helena Tlaskalová-Hogenová. Contribution of infectious agents to the development of celiac disease. Microorganisms, 9:547, Mar 2021. URL: https://doi.org/10.3390/microorganisms9030547, doi:10.3390/microorganisms9030547. This article has 16 citations and is from a peer-reviewed journal.

---

Query 2: Given the following hypothesis (and rationale) about the pathogenesis of celiac disease, find scientific evidence to support and/or refute this hypothesis.
Format your response with the following headings: **Supporting evidence**: <supporting info>, **Countering evidence**: <refutation>, **Conclusion**: <conclusion>

Hypothesis: Hypothesis: : Parasitic helminths modulate regulatory T-cell populations through metabolic reprogramming, and their absence in developed countries contributes to loss of immune tolerance to dietary antigens including gluten proteins.
Rationale: : The hygiene hypothesis suggests reduced parasitic exposure correlates with autoimmune disease prevalence. Helminths induce Treg expansion through metabolic shifts favoring oxidative phosphorylation over glycolysis.
Answer 2: Okay, this is an interesting and plausible hypothesis that builds on several established immunological concepts. Let's break down the evidence.

**Supporting evidence**:

1.  **The Hygiene Hypothesis and Autoimmune Disease:** There's broad epidemiological evidence supporting the hygiene hypothesis, which posits that reduced exposure to microbes and parasites in early life in developed countries leads to an improperly calibrated immune system, increasing susceptibility to allergic and autoimmune diseases. Celiac disease incidence has been rising in Western countries, consistent with this trend.
    *   *Example:* Studies have shown lower rates of autoimmune diseases like Type 1 Diabetes and Multiple Sclerosis in populations with higher helminth prevalence. While not specific to celiac, it supports the general premise.
2.  **Helminth Induction of Regulatory T cells (Tregs):** Numerous studies in animal models and humans demonstrate that helminth infections potently induce the expansion and activation of Treg populations. These Tregs are crucial for maintaining immune homeostasis and preventing autoimmunity.
    *   *Example:* Infections with *Heligmosomoides polygyrus* in mice, or *Schistosoma mansoni*, are well-documented to increase Foxp3+ Treg numbers and their suppressive function, often mediated by cytokines like IL-10 and TGF-β.
3.  **Treg Dysfunction in Celiac Disease:** Patients with active celiac disease often show defects in Treg numbers or function in the gut mucosa. While Tregs are present, their ability to suppress the inflammatory response to gluten peptides appears compromised.
    *   *Example:* Some studies indicate that while Treg numbers might be elevated in the celiac lesion, their suppressive capacity against gluten-specific effector T cells is insufficient.
4.  **Metabolic Reprogramming of Tregs:** The metabolic state of T cells dictates their function. Effector T cells often rely on glycolysis for rapid proliferation and cytokine production, while Tregs are increasingly understood to favor oxidative phosphorylation (OXPHOS) for sustained suppressive activity and longevity.
    *   *Example:* Research shows that promoting OXPHOS in Tregs enhances their stability and suppressive function. Conversely, inhibiting OXPHOS can impair Treg function.
5.  **Helminth-Mediated Metabolic Shifts in Tregs:** Emerging evidence suggests that helminths or their products can directly influence immune cell metabolism. Some helminth-derived molecules have been shown to drive macrophages towards an M2 (anti-inflammatory) phenotype, which also relies on OXPHOS. It's plausible they exert similar effects on Tregs.
    *   *Example:* While direct evidence for helminths reprogramming Treg metabolism specifically towards OXPHOS is still an active area of research, studies on helminth-derived immunomodulatory molecules show they can alter host cell metabolic pathways (e.g., fatty acid oxidation, which feeds into OXPHOS) in ways that favor regulatory responses. For instance, schistosome-derived lysophosphatidylserine can induce M2 macrophages, which are metabolically distinct.
6.  **Animal Models of Helminth Protection in Gut Inflammation:** Animal models of intestinal inflammation (like colitis, which shares some inflammatory pathways with celiac disease, though distinct in antigen specificity) have shown that helminth infection or administration of helminth-derived products can ameliorate disease, often in a Treg-dependent manner.
    *   *Example:* In mouse models of colitis, infection with *Trichuris muris* or *H. polygyrus* can protect against disease, an effect often associated with increased Treg activity and IL-10 production.

**Countering evidence**:

1.  **Complexity of Celiac Disease Etiology:** Celiac disease has a strong genetic predisposition (HLA-DQ2/DQ8 is present in >95% of patients) and gluten is the definite environmental trigger. While the hygiene hypothesis is relevant, genetics plays a dominant, indispensable role. Helminth absence would be a *contributing* factor to loss of tolerance, not the sole or primary cause.
2.  **Inconsistent Epidemiological Data for Celiac Disease and Helminths Specifically:** While the general hygiene hypothesis is strong, direct epidemiological studies robustly linking low helminth prevalence *specifically* to increased celiac disease rates are less common or sometimes show mixed results compared to other autoimmune diseases like IBD or MS. Some regions with historically high helminth burdens are also seeing rising celiac disease rates as they develop.
3.  **Variability in Helminth Species and Effects:** Not all helminths are created equal. Different species induce different types of immune responses. Some can even exacerbate certain inflammatory conditions or cause pathology themselves. The specific helminth, dose, and timing of exposure would be critical.
4.  **Other Mechanisms of Helminth Immunomodulation:** Helminths modulate the immune system through a vast array of mechanisms beyond Treg metabolic reprogramming, including direct effects on dendritic cells, induction of type 2 cytokines (IL-4, IL-5, IL-13), B-cell regulation, and modification of the gut microbiome. Attributing protection solely to Treg metabolic reprogramming might be an oversimplification.
5.  **Limited Success of Helminth Therapy in Humans for Autoimmunity:** Clinical trials using live helminths (e.g., *Trichuris suis ova*) or their products for autoimmune diseases like Crohn's disease, ulcerative colitis, and multiple sclerosis have yielded mixed and often modest results. While some individuals benefit, it's not a universal cure, and the effects for celiac disease specifically have not been extensively tested.
6.  **Treg Metabolism is Complex:** While OXPHOS is important for Treg stability and function, Tregs can also utilize glycolysis under certain conditions. The precise metabolic requirements can be context-dependent. The link between helminth-induced global metabolic shifts and specific functional outcomes in Tregs within the gluten-specific response needs more direct evidence.
7.  **Focus on Absence:** The hypothesis focuses on the *absence* of helminths. However, other factors associated with "westernized" lifestyles, such as diet (beyond gluten, e.g., processed foods), antibiotic use, and gut microbiota dysbiosis, are also strong candidates for contributing to immune dysregulation and celiac disease development.

**Conclusion**:

The hypothesis that the absence of parasitic helminths contributes to celiac disease pathogenesis via impaired Treg modulation (specifically through metabolic reprogramming towards OXPHOS) is plausible and supported by several lines of indirect and mechanistic evidence.
*   **Strengths:** It aligns with the broader hygiene hypothesis, the known role of helminths in inducing Tregs, the importance of Tregs in maintaining tolerance, and the emerging understanding of immunometabolism.
*   **Weaknesses/Gaps:** Direct evidence linking helminth-induced *metabolic reprogramming of Tregs* to protection *specifically against gluten intolerance* in humans is still lacking. The epidemiological link between helminths and celiac disease is not as robust as for some other autoimmune conditions. Celiac disease has a very strong genetic component that is paramount.

Overall, the proposed mechanism is a compelling part of a larger, multifactorial picture. While the absence of helminth-driven immune education, including potential effects on Treg metabolism, likely contributes to the rising prevalence of celiac disease in developed countries, it is unlikely to be the sole or primary driver. It's more probable that it's one of several environmental factors interacting with genetic susceptibility to breach oral tolerance to gluten. Further research is needed to specifically demonstrate that helminth-induced metabolic reprogramming of Tregs plays a critical role in maintaining tolerance to gluten and that its absence is a key factor in celiac disease development.
References 2:


---

Query 3: Given the following hypothesis (and rationale) about the pathogenesis of celiac disease, find scientific evidence to support and/or refute this hypothesis.
Format your response with the following headings: **Supporting evidence**: <supporting info>, **Countering evidence**: <refutation>, **Conclusion**: <conclusion>

Hypothesis: Hypothesis: : Dysregulated tryptophan metabolism via the kynurenine pathway creates an immunosuppressive microenvironment that paradoxically promotes Th17 cell differentiation and IL-17-mediated tissue damage in celiac disease patients.
Rationale: : Tryptophan catabolism through IDO1/TDO2 produces kynurenine metabolites. While generally immunosuppressive, certain kynurenines can promote Th17 responses under inflammatory conditions, explaining celiac pathology.
Answer 3: **Supporting evidence**:
Evidence indicates dysregulation of tryptophan metabolism via the kynurenine pathway in celiac disease (CeD). Studies report increased urinary excretion of kynurenine (Kyn), kynurenic acid (KA), and xanthurenic acid (XA) in untreated adult CeD patients, a response markedly amplified by L-tryptophan loading, suggesting enhanced activity of this metabolic branch independent of gut bacterial flora (kowlessar1964abnormaltryptophanmetabolism pages 5-6). Indoleamine 2,3-dioxygenase (IDO) enzyme expression is enhanced in the small intestine of individuals with CeD (asgari2024theroleof pages 10-11). IDO1, catalyzing tryptophan catabolism, is induced by inflammatory mediators such as IFN-γ and TNF-α in antigen-presenting cells (APCs) in CeD (asgari2024theroleof pages 4-6). Fecal kynurenine is increased in active CeD patients, and alterations in kynurenine pathway metabolites (xanthurenic and kynurenic acid) are observed (lamas2020arylhydrocarbonreceptor pages 7-8, lamas2020arylhydrocarbonreceptor pages 6-7).

The kynurenine pathway is generally understood to create an immunosuppressive microenvironment by promoting oral tolerance to dietary antigens, inducing T cell apoptosis, promoting regulatory T cell (Treg) differentiation, and inhibiting effector T cell proliferation (asgari2024theroleof pages 10-11, asgari2024theroleof pages 4-6, asgari2024theroleof pages 6-8, asgari2024theroleof pages 8-10, cribbs2015roleofthe pages 1-4, renga2019tobeor pages 3-4, fallah2024investigatingtheimpact pages 12-12).

However, there is emerging evidence suggesting that certain Aryl Hydrocarbon Receptor (AhR) ligands derived from tryptophan metabolism, potentially including kynurenine metabolites, may paradoxically promote Th17 cell differentiation and IL-17 production in some inflammatory settings (asgari2024theroleof pages 10-11, asgari2024theroleof pages 4-6, asgari2024theroleof pages 6-8, asgari2024theroleof pages 8-10, lamas2020arylhydrocarbonreceptor pages 7-8, lamas2020arylhydrocarbonreceptor pages 6-7, cribbs2015roleofthe pages 1-4, renga2019tobeor pages 3-4, fallah2024investigatingtheimpact pages 12-12). The IL-17/Th17 axis is implicated in CeD, contributing to enhanced intestinal permeability and mucosal damage (gorini2024vitamindan pages 9-11).

**Countering evidence**:
Despite the potential for paradoxical Th17 promotion by kynurenines, several lines of evidence complicate this hypothesis in the context of CeD, particularly regarding AhR-mediated mechanisms. Studies in active CeD report *decreased* AhR ligand production by gut microbiota, *reduced* intestinal AhR pathway activation, and *lower* duodenal mucosal expression of AhR pathway genes, including *IL-17* (Lamas et al. 2020 in NCT05576038, lamas2020arylhydrocarbonreceptor pages 1-1, lamas2020arylhydrocarbonreceptor pages 6-7, lamas2020arylhydrocarbonreceptor pages 6-7, lamas2020arylhydrocarbonreceptor pages 7-8, lamas2020arylhydrocarbonreceptor pages 7-8, huang2024therapeuticpotentialof pages 12-13). Defective or diminished AhR signaling is observed in active CeD mucosa (renga2019tobeor pages 3-4, renga2019tobeor pages 3-4, dinallo2019protectiveeffectsof pages 8-9, bahman2024arylhydrocarbonreceptor pages 17-17). Specifically, in active CeD, defective AhR signaling is linked to *reduced*, not increased, IL-17 expression (NCT05576038). This makes it less likely that kynurenines are promoting IL-17 via broad AhR pathway activation if the pathway itself and its target gene IL-17 are downregulated.

The evidence linking kynurenine metabolites promoting Th17 via AhR in CeD is considered weak, contradictory, or context-dependent (NCT05576038, lamas2020arylhydrocarbonreceptor pages 6-7, bahman2024arylhydrocarbonreceptor pages 17-17, huang2024therapeuticpotentialof pages 12-13). It's suggested that any kynurenine-driven Th17 promotion might occur independently of, or despite, global AhR pathway impairment in CeD (NCT05576038, bahman2024arylhydrocarbonreceptor pages 17-17).

Furthermore, direct evidence linking dysregulated kynurenine metabolism as a significant driver of IL-17-mediated tissue damage in CeD patients is limited. The Open Targets Platform shows limited direct associations for IDO1 with celiac disease and no direct evidence entries for IL17A or IL17F (OpenTargets Search: Celiac disease-IDO1,TDO2,AHR,RORC,STAT3,IL17A,IL17F, OpenTargets Search: Celiac disease-IDO1,TDO2,AHR,RORC,STAT3,IL17A,IL17F). The platform does not provide robust support for dysregulated kynurenine metabolism driving IL-17 pathology in CeD (OpenTargets Search: Celiac disease-IDO1,TDO2,AHR,RORC,STAT3,IL17A,IL17F, lamas2020arylhydrocarbonreceptor pages 6-7). Clinical trial data are also scarce; only one trial (NCT05576038) was identified in searches, and it focuses on restoring AhR signaling with L-tryptophan (targeting indole production by microbiota) rather than addressing kynurenine pathway dysregulation or IL-17 (Clinical Trial Search: AREA[Condition]"celiac disease" AND (AREA[Keyword]tryptophan OR AREA[Keyword]kynurenine OR AREA[Keyword]IDO1 OR AREA[Keyword]TDO2 OR AREA[Keyword]"Th17" OR AREA[Keyword]"IL-17" OR AREA[Keyword]"AHR"), Clinical Trial Search: AREA[Condition]"celiac disease" AND (AREA[Keyword]tryptophan OR AREA[Keyword]kynurenine OR AREA[Keyword]IDO1 OR AREA[Keyword]TDO2 OR AREA[Keyword]"Th17" OR AREA[Keyword]"IL-17" OR AREA[Keyword]"AHR"), Clinical Trial Search: AREA[Condition]"celiac disease" AND (AREA[Keyword]tryptophan OR AREA[Keyword]kynurenine OR AREA[Keyword]IDO1 OR AREA[Keyword]TDO2 OR AREA[Keyword]"Th17" OR AREA[Keyword]"IL-17" OR AREA[Keyword]"AHR"), NCT05576038, NCT05576038).

**Conclusion**:
Tryptophan metabolism via the kynurenine pathway is demonstrably dysregulated in celiac disease, with altered IDO activity and kynurenine metabolite levels (kowlessar1964abnormaltryptophanmetabolism pages 5-6, asgari2024theroleof pages 10-11, lamas2020arylhydrocarbonreceptor pages 7-8). While this pathway typically fosters immunosuppression, some kynurenine metabolites possess the potential to paradoxically promote Th17 differentiation and IL-17 production in inflammatory contexts (asgari2024theroleof pages 10-11, cribbs2015roleofthe pages 1-4), and IL-17 is involved in CeD pathogenesis (gorini2024vitamindan pages 9-11).

However, the hypothesis that this paradoxical Th17 promotion by kynurenines *via AhR activation* significantly drives IL-17-mediated tissue damage in CeD is challenged by observations of *impaired* AhR signaling and *reduced* AhR pathway gene expression (including IL-17 mRNA) in active CeD (NCT05576038, lamas2020arylhydrocarbonreceptor pages 6-7, renga2019tobeor pages 3-4). The direct evidence for kynurenine-driven, AhR-mediated IL-17 pathology in CeD remains weak, contradictory, and under-investigated (OpenTargets Search: Celiac disease-IDO1,TDO2,AHR,RORC,STAT3,IL17A,IL17F, Clinical Trial Search: AREA[Condition]"celiac disease" AND (AREA[Keyword]tryptophan OR AREA[Keyword]kynurenine OR AREA[Keyword]IDO1 OR AREA[Keyword]TDO2 OR AREA[Keyword]"Th17" OR AREA[Keyword]"IL-17" OR AREA[Keyword]"AHR"), lamas2020arylhydrocarbonreceptor pages 6-7). If kynurenines contribute to Th17 responses in CeD, the mechanism may be context-dependent, AhR-independent, or occur despite an overall reduction in canonical AhR pathway activity.
References 3:
1. (NCT05576038): David Armstrong. Tryptophan for Impaired AhR Signaling in Celiac Disease. McMaster University. 2022. ClinicalTrials.gov Identifier: NCT05576038

2. (OpenTargets Search: Celiac disease-IDO1,TDO2,AHR,RORC,STAT3,IL17A,IL17F): Open Targets Query (Celiac disease-IDO1,TDO2,AHR,RORC,STAT3,IL17A,IL17F, 24 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

3. (asgari2024theroleof pages 10-11): Fatemeh Asgari, Mahdi Khodadoust, Abdolrahim Nikzamir, Somayeh Jahani‐Sherafat, Mostafa Rezaei Tavirani, and Mohammad Rostami‐Nejad. The role of tryptophan metabolism and tolerogenic dendritic cells in maintaining immune tolerance: insights into celiac disease pathogenesis. Immunity, Inflammation and Disease, Aug 2024. URL: https://doi.org/10.1002/iid3.1354, doi:10.1002/iid3.1354. This article has 3 citations and is from a peer-reviewed journal.

4. (asgari2024theroleof pages 4-6): Fatemeh Asgari, Mahdi Khodadoust, Abdolrahim Nikzamir, Somayeh Jahani‐Sherafat, Mostafa Rezaei Tavirani, and Mohammad Rostami‐Nejad. The role of tryptophan metabolism and tolerogenic dendritic cells in maintaining immune tolerance: insights into celiac disease pathogenesis. Immunity, Inflammation and Disease, Aug 2024. URL: https://doi.org/10.1002/iid3.1354, doi:10.1002/iid3.1354. This article has 3 citations and is from a peer-reviewed journal.

5. (asgari2024theroleof pages 6-8): Fatemeh Asgari, Mahdi Khodadoust, Abdolrahim Nikzamir, Somayeh Jahani‐Sherafat, Mostafa Rezaei Tavirani, and Mohammad Rostami‐Nejad. The role of tryptophan metabolism and tolerogenic dendritic cells in maintaining immune tolerance: insights into celiac disease pathogenesis. Immunity, Inflammation and Disease, Aug 2024. URL: https://doi.org/10.1002/iid3.1354, doi:10.1002/iid3.1354. This article has 3 citations and is from a peer-reviewed journal.

6. (asgari2024theroleof pages 8-10): Fatemeh Asgari, Mahdi Khodadoust, Abdolrahim Nikzamir, Somayeh Jahani‐Sherafat, Mostafa Rezaei Tavirani, and Mohammad Rostami‐Nejad. The role of tryptophan metabolism and tolerogenic dendritic cells in maintaining immune tolerance: insights into celiac disease pathogenesis. Immunity, Inflammation and Disease, Aug 2024. URL: https://doi.org/10.1002/iid3.1354, doi:10.1002/iid3.1354. This article has 3 citations and is from a peer-reviewed journal.

7. (kowlessar1964abnormaltryptophanmetabolism pages 5-6): O. Dhodanand Kowlessar, Lorraine J. Haeffner, and Gordon D. Benson. Abnormal tryptophan metabolism in patients with adult celiac disease, with evidence for deficiency of vitamin b6*. Journal of Clinical Investigation, 43:894-903, May 1964. URL: https://doi.org/10.1172/jci104975, doi:10.1172/jci104975. This article has 53 citations and is from a highest quality peer-reviewed journal.

8. (lamas2020arylhydrocarbonreceptor pages 1-1): Bruno Lamas, Leticia Hernandez-Galan, Heather J. Galipeau, Marco Constante, Alexandra Clarizio, Jennifer Jury, Natalia M. Breyner, Alberto Caminero, Gaston Rueda, Christina L. Hayes, Justin L. McCarville, Miriam Bermudez Brito, Julien Planchais, Nathalie Rolhion, Joseph A. Murray, Philippe Langella, Linda M. P. Loonen, Jerry M. Wells, Premysl Bercik, Harry Sokol, and Elena F. Verdu. Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Science Translational Medicine, Oct 2020. URL: https://doi.org/10.1126/scitranslmed.aba0624, doi:10.1126/scitranslmed.aba0624. This article has 155 citations and is from a highest quality peer-reviewed journal.

9. (lamas2020arylhydrocarbonreceptor pages 6-7): Bruno Lamas, Leticia Hernandez-Galan, Heather J. Galipeau, Marco Constante, Alexandra Clarizio, Jennifer Jury, Natalia M. Breyner, Alberto Caminero, Gaston Rueda, Christina L. Hayes, Justin L. McCarville, Miriam Bermudez Brito, Julien Planchais, Nathalie Rolhion, Joseph A. Murray, Philippe Langella, Linda M. P. Loonen, Jerry M. Wells, Premysl Bercik, Harry Sokol, and Elena F. Verdu. Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Science Translational Medicine, Oct 2020. URL: https://doi.org/10.1126/scitranslmed.aba0624, doi:10.1126/scitranslmed.aba0624. This article has 155 citations and is from a highest quality peer-reviewed journal.

10. (lamas2020arylhydrocarbonreceptor pages 7-8): Bruno Lamas, Leticia Hernandez-Galan, Heather J. Galipeau, Marco Constante, Alexandra Clarizio, Jennifer Jury, Natalia M. Breyner, Alberto Caminero, Gaston Rueda, Christina L. Hayes, Justin L. McCarville, Miriam Bermudez Brito, Julien Planchais, Nathalie Rolhion, Joseph A. Murray, Philippe Langella, Linda M. P. Loonen, Jerry M. Wells, Premysl Bercik, Harry Sokol, and Elena F. Verdu. Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Science Translational Medicine, Oct 2020. URL: https://doi.org/10.1126/scitranslmed.aba0624, doi:10.1126/scitranslmed.aba0624. This article has 155 citations and is from a highest quality peer-reviewed journal.

11. (bahman2024arylhydrocarbonreceptor pages 17-17): Fatemah Bahman, Khubaib Choudhry, Fatema Al-Rashed, Fahd Al-Mulla, Sardar Sindhu, and Rasheed Ahmad. Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1421346, doi:10.3389/fimmu.2024.1421346. This article has 7 citations and is from a peer-reviewed journal.

12. (cribbs2015roleofthe pages 1-4): Adam P. Cribbs and Richard O. Williams. Role of the kynurenine pathway in immune-mediated inflammation. Unknown journal, pages 93-107, Dec 2015. URL: https://doi.org/10.1007/978-3-319-11870-3\_7, doi:10.1007/978-3-319-11870-3\_7. This article has 6 citations.

13. (dinallo2019protectiveeffectsof pages 8-9): Vincenzo Dinallo, Irene Marafini, Davide Di Fusco, Antonio Di Grazia, Federica Laudisi, Rami Dwairi, Omero A. Paoluzi, Giovanni Monteleone, and Ivan Monteleone. Protective effects of aryl hydrocarbon receptor signaling in celiac disease mucosa and in poly i:c-induced small intestinal atrophy mouse model. Frontiers in Immunology, Feb 2019. URL: https://doi.org/10.3389/fimmu.2019.00091, doi:10.3389/fimmu.2019.00091. This article has 27 citations and is from a peer-reviewed journal.

14. (gorini2024vitamindan pages 9-11): Francesca Gorini and Alessandro Tonacci. Vitamin d: an essential nutrient in the dual relationship between autoimmune thyroid diseases and celiac disease—a comprehensive review. Nutrients, 16:1762, Jun 2024. URL: https://doi.org/10.3390/nu16111762, doi:10.3390/nu16111762. This article has 6 citations and is from a peer-reviewed journal.

15. (huang2024therapeuticpotentialof pages 12-13): Fu-Chen Huang. Therapeutic potential of nutritional aryl hydrocarbon receptor ligands in gut-related inflammation and diseases. Biomedicines, 12:2912, Dec 2024. URL: https://doi.org/10.3390/biomedicines12122912, doi:10.3390/biomedicines12122912. This article has 1 citations and is from a peer-reviewed journal.

16. (renga2019tobeor pages 3-4): Giorgia Renga, Marina M. Bellet, Claudia Stincardini, Marilena Pariano, Vasilis Oikonomou, Valeria R. Villella, Stefano Brancorsini, Carlo Clerici, Luigina Romani, and Claudio Costantini. To be or not to be a pathogen: candida albicans and celiac disease. Frontiers in Immunology, Dec 2019. URL: https://doi.org/10.3389/fimmu.2019.02844, doi:10.3389/fimmu.2019.02844. This article has 12 citations and is from a peer-reviewed journal.

17. (fallah2024investigatingtheimpact pages 12-12): Shayan Fallah, Nastaran Asri, Abdolrahim Nikzamir, Shokoufeh Ahmadipour, Amir Sadeghi, Kamran Rostami, and Mohammad Rostami-Nejad. Investigating the impact of vitamin a and amino acids on immune responses in celiac disease patients. Diseases, 12:13, Jan 2024. URL: https://doi.org/10.3390/diseases12010013, doi:10.3390/diseases12010013. This article has 6 citations and is from a peer-reviewed journal.

---

Query 4: Given the following hypothesis (and rationale) about the pathogenesis of celiac disease, find scientific evidence to support and/or refute this hypothesis.
Format your response with the following headings: **Supporting evidence**: <supporting info>, **Countering evidence**: <refutation>, **Conclusion**: <conclusion>

Hypothesis: Hypothesis: : Congenital variations in intestinal stem cell niche architecture predispose to aberrant crypt development, creating microenvironments where gluten-reactive T cells preferentially expand and maintain pathogenic memory responses.
Rationale: : Intestinal stem cell niches show individual variation in structure and cellular composition. Altered niche architecture could create specialized microenvironments that favor pathogenic T cell persistence and reactivation.
Answer 4: **Supporting evidence**:
Evidence suggests that inherent or congenital variations in intestinal stem cell (ISC) niche architecture or related epithelial characteristics might contribute to celiac disease (CD) predisposition. Organoid studies indicate potential inherent differences in ISC niche architecture in CD, with gene expression patterns hinting that congenital variations in the ISC niche may predispose to CD development (freire2019humangutderivedorganoids pages 2-3). Such congenital variations could manifest as altered intestinal barrier function, which has been observed even in healthy first-degree relatives of CD patients, suggesting barrier defects may precede disease onset (schumann2017celiacdiseaserole pages 5-7). An impaired epithelial barrier, potentially stemming from these congenital variations, could facilitate the presentation of immunogenic gluten peptides, thereby promoting the activation and maintenance of pathogenic gluten-reactive T cells within this altered microenvironment (schumann2017celiacdiseaserole pages 5-7). Furthermore, potentially inherited differences in the complex cellular and molecular networks that define the ISC niche could alter stem cell niche behavior and intestinal homeostasis (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14). These inherited variations affecting intestinal stem cell niches could shape immune cell behavior, for instance, by contributing to shifts in morphogen signaling that foster a hyperproliferative epithelial environment with increased expression of chemokines like CCL25; this chemokine is implicated in recruiting T cells and supporting their expansion and memory maintenance in specialized lymphoid niches (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 14-15, fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14). Indeed, the microenvironment in CD, characterized by specific cytokines (e.g., CCL25, IL-21) and chemokines, is known to support the preferential expansion and maintenance of pathogenic T cells and sustain lymphoid aggregates (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14, piscaglia2014intestinalstemcells pages 8-9). While some Paneth cell and crypt abnormalities observed in CD might be secondary to inflammation, the possibility of them being primary congenital defects remains (schumann2017celiacdiseaserole pages 5-7).

**Countering evidence**:
A significant portion of the provided context indicates that aberrant crypt development, including crypt hyperplasia, is predominantly a consequence of inflammation rather than a result of congenital niche variations (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14, siukola2024spatialtranscriptomicsof pages 15-19, hisamatsu2016theroleof pages 1-2, senger2015celiacdiseasehistopathology pages 15-15, voisine2021interplaybetweengluten pages 2-4, piscaglia2014intestinalstemcells pages 9-10, freire2019humangutderivedorganoids pages 12-13, voisine2021interplaybetweengluten pages 6-7). Pathological crypt development and structural changes like villous atrophy are described as secondary responses to inflammation and immune-mediated tissue remodeling (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14, siukola2024spatialtranscriptomicsof pages 15-19, hisamatsu2016theroleof pages 1-2, senger2015celiacdiseasehistopathology pages 15-15). Current data are interpreted as primarily supporting ISC niche changes as disease-driven adaptive or pathological responses, rather than pre-existing congenital variations that predispose to CD (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 1-2, senger2015celiacdiseasehistopathology pages 9-11). Several sources explicitly state a lack of direct scientific evidence or that studies do not provide direct evidence for congenital variations in ISC niche architecture as a cause or predisposing factor for CD (piscaglia2015circulatinghematopoieticstem pages 4-5, dieterich2020intestinalexvivo pages 8-9, freire2019humangutderivedorganoids pages 1-2, hidray2023cytokinesinfluencegut pages 12-17, hidray2023cytokinesinfluencegut pages 65-68, piscaglia2014intestinalstemcells pages 10-11, piscaglia2014intestinalstemcells pages 5-7, senger2015celiacdiseasehistopathology pages 14-15). T cell responses are described as being heavily influenced by secondary inflammatory signals and the altered microenvironment, rather than congenital crypt niche variations (voisine2021interplaybetweengluten pages 2-4).

**Conclusion**:
The provided context offers limited direct support for the hypothesis that congenital variations in intestinal stem cell niche architecture are a primary predisposing factor for aberrant crypt development leading to microenvironments that favor gluten-reactive T cell expansion in celiac disease. While some evidence from organoid models and observations in asymptomatic relatives suggests that inherent or inherited differences in epithelial barrier function or ISC niche characteristics could influence susceptibility and potentially shape immune cell behavior (freire2019humangutderivedorganoids pages 2-3, schumann2017celiacdiseaserole pages 5-7, fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 14-15), the predominant view presented is that alterations in crypt architecture and the ISC niche are secondary consequences of the gluten-induced inflammatory response (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14, siukola2024spatialtranscriptomicsof pages 15-19, hisamatsu2016theroleof pages 1-2). Many sources explicitly note a lack of direct evidence supporting a primary role for congenital niche variations in CD pathogenesis (piscaglia2015circulatinghematopoieticstem pages 4-5, fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 1-2). Therefore, based on this context, while congenital factors might play a subtle predisposing role, aberrant crypt development and associated pathogenic T cell responses in celiac disease appear more robustly linked to inflammation-induced phenomena.
References 4:
1. (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 13-14): Michael E. B. FitzPatrick, Agne Antanaviciute, Melanie Dunstan, Karolina Künnapuu, Dominik Trzupek, Nicholas M. Provine, Kyla Dooley, Jia-Yuan Zhang, Sophie L. Irwin, Lucy C. Garner, Jane I. Pernes, Ricardo C. Ferreira, Sarah C. Sasson, Dominik Aschenbrenner, Devika Agarwal, Astor Rodrigues, Lucy Howarth, Oliver Brain, Darren Ruane, Elizabeth Soilleux, Sarah A. Teichmann, Calliope A. Dendrou, Alison Simmons, Holm H. Uhlig, John A. Todd, and Paul Klenerman. Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease. Nature Immunology, 26:947-962, May 2025. URL: https://doi.org/10.1038/s41590-025-02146-2, doi:10.1038/s41590-025-02146-2. This article has 0 citations and is from a highest quality peer-reviewed journal.

2. (piscaglia2014intestinalstemcells pages 8-9): Anna Chiara Piscaglia. Intestinal stem cells and celiac disease. World Journal of Stem Cells, 6:213, Jan 2014. URL: https://doi.org/10.4252/wjsc.v6.i2.213, doi:10.4252/wjsc.v6.i2.213. This article has 29 citations.

3. (schumann2017celiacdiseaserole pages 5-7): Michael Schumann, Britta Siegmund, Jörg D. Schulzke, and Michael Fromm. Celiac disease: role of the epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 3:150-162, Mar 2017. URL: https://doi.org/10.1016/j.jcmgh.2016.12.006, doi:10.1016/j.jcmgh.2016.12.006. This article has 216 citations and is from a domain leading peer-reviewed journal.

4. (siukola2024spatialtranscriptomicsof pages 15-19): E Siukola. Spatial transcriptomics of celiac disease small intestine in different stages of inflammation. Unknown journal, 2024.

5. (freire2019humangutderivedorganoids pages 2-3): Rachel Freire, Laura Ingano, Gloria Serena, Murat Cetinbas, Anthony Anselmo, Anna Sapone, Ruslan I. Sadreyev, Alessio Fasano, and Stefania Senger. Human gut derived-organoids provide model to study gluten response and effects of microbiota-derived molecules in celiac disease. Scientific Reports, May 2019. URL: https://doi.org/10.1038/s41598-019-43426-w, doi:10.1038/s41598-019-43426-w. This article has 125 citations and is from a poor quality or predatory journal.

6. (hidray2023cytokinesinfluencegut pages 12-17): TY Hidray. Cytokines influence gut duodenal epithelial cells differentiation and celiac disease development. Unknown journal, 2023.

7. (hisamatsu2016theroleof pages 1-2): Tadakazu Hisamatsu, Ulrike Erben, and Anja A. Kühl. The role of t-cell subsets in chronic inflammation in celiac disease and inflammatory bowel disease patients: more common mechanisms or more differences? Inflammatory Intestinal Diseases, 1:52-62, Apr 2016. URL: https://doi.org/10.1159/000445133, doi:10.1159/000445133. This article has 33 citations.

8. (piscaglia2014intestinalstemcells pages 9-10): Anna Chiara Piscaglia. Intestinal stem cells and celiac disease. World Journal of Stem Cells, 6:213, Jan 2014. URL: https://doi.org/10.4252/wjsc.v6.i2.213, doi:10.4252/wjsc.v6.i2.213. This article has 29 citations.

9. (piscaglia2015circulatinghematopoieticstem pages 4-5): Anna Chiara Piscaglia, Sergio Rutella, Lucrezia Laterza, Valentina Cesario, Mariachiara Campanale, Immacolata Alessia Cazzato, Gianluca Ianiro, Federico Barbaro, Luca Di Maurizio, Giuseppina Bonanno, Tonia Cenci, Giovanni Cammarota, Luigi Maria Larocca, and Antonio Gasbarrini. Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. Journal of Translational Medicine, Jul 2015. URL: https://doi.org/10.1186/s12967-015-0591-0, doi:10.1186/s12967-015-0591-0. This article has 24 citations and is from a peer-reviewed journal.

10. (senger2015celiacdiseasehistopathology pages 14-15): Stefania Senger, Anna Sapone, Maria Rosaria Fiorentino, Giuseppe Mazzarella, Gregory Y. Lauwers, and Alessio Fasano. Celiac disease histopathology recapitulates hedgehog downregulation, consistent with wound healing processes activation. PLOS ONE, 10:e0144634, Dec 2015. URL: https://doi.org/10.1371/journal.pone.0144634, doi:10.1371/journal.pone.0144634. This article has 39 citations and is from a peer-reviewed journal.

11. (senger2015celiacdiseasehistopathology pages 15-15): Stefania Senger, Anna Sapone, Maria Rosaria Fiorentino, Giuseppe Mazzarella, Gregory Y. Lauwers, and Alessio Fasano. Celiac disease histopathology recapitulates hedgehog downregulation, consistent with wound healing processes activation. PLOS ONE, 10:e0144634, Dec 2015. URL: https://doi.org/10.1371/journal.pone.0144634, doi:10.1371/journal.pone.0144634. This article has 39 citations and is from a peer-reviewed journal.

12. (senger2015celiacdiseasehistopathology pages 9-11): Stefania Senger, Anna Sapone, Maria Rosaria Fiorentino, Giuseppe Mazzarella, Gregory Y. Lauwers, and Alessio Fasano. Celiac disease histopathology recapitulates hedgehog downregulation, consistent with wound healing processes activation. PLOS ONE, 10:e0144634, Dec 2015. URL: https://doi.org/10.1371/journal.pone.0144634, doi:10.1371/journal.pone.0144634. This article has 39 citations and is from a peer-reviewed journal.

13. (voisine2021interplaybetweengluten pages 2-4): Jordan Voisine and Valérie Abadie. Interplay between gluten, hla, innate and adaptive immunity orchestrates the development of coeliac disease. Frontiers in Immunology, Jun 2021. URL: https://doi.org/10.3389/fimmu.2021.674313, doi:10.3389/fimmu.2021.674313. This article has 53 citations and is from a peer-reviewed journal.

14. (dieterich2020intestinalexvivo pages 8-9): Walburga Dieterich, Markus F. Neurath, and Yurdagül Zopf. Intestinal ex vivo organoid culture reveals altered programmed crypt stem cells in patients with celiac disease. Scientific Reports, Feb 2020. URL: https://doi.org/10.1038/s41598-020-60521-5, doi:10.1038/s41598-020-60521-5. This article has 41 citations and is from a poor quality or predatory journal.

15. (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 1-2): Michael E. B. FitzPatrick, Agne Antanaviciute, Melanie Dunstan, Karolina Künnapuu, Dominik Trzupek, Nicholas M. Provine, Kyla Dooley, Jia-Yuan Zhang, Sophie L. Irwin, Lucy C. Garner, Jane I. Pernes, Ricardo C. Ferreira, Sarah C. Sasson, Dominik Aschenbrenner, Devika Agarwal, Astor Rodrigues, Lucy Howarth, Oliver Brain, Darren Ruane, Elizabeth Soilleux, Sarah A. Teichmann, Calliope A. Dendrou, Alison Simmons, Holm H. Uhlig, John A. Todd, and Paul Klenerman. Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease. Nature Immunology, 26:947-962, May 2025. URL: https://doi.org/10.1038/s41590-025-02146-2, doi:10.1038/s41590-025-02146-2. This article has 0 citations and is from a highest quality peer-reviewed journal.

16. (fitzpatrick2025immune–epithelial–stromalnetworksdefine pages 14-15): Michael E. B. FitzPatrick, Agne Antanaviciute, Melanie Dunstan, Karolina Künnapuu, Dominik Trzupek, Nicholas M. Provine, Kyla Dooley, Jia-Yuan Zhang, Sophie L. Irwin, Lucy C. Garner, Jane I. Pernes, Ricardo C. Ferreira, Sarah C. Sasson, Dominik Aschenbrenner, Devika Agarwal, Astor Rodrigues, Lucy Howarth, Oliver Brain, Darren Ruane, Elizabeth Soilleux, Sarah A. Teichmann, Calliope A. Dendrou, Alison Simmons, Holm H. Uhlig, John A. Todd, and Paul Klenerman. Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease. Nature Immunology, 26:947-962, May 2025. URL: https://doi.org/10.1038/s41590-025-02146-2, doi:10.1038/s41590-025-02146-2. This article has 0 citations and is from a highest quality peer-reviewed journal.

17. (freire2019humangutderivedorganoids pages 1-2): Rachel Freire, Laura Ingano, Gloria Serena, Murat Cetinbas, Anthony Anselmo, Anna Sapone, Ruslan I. Sadreyev, Alessio Fasano, and Stefania Senger. Human gut derived-organoids provide model to study gluten response and effects of microbiota-derived molecules in celiac disease. Scientific Reports, May 2019. URL: https://doi.org/10.1038/s41598-019-43426-w, doi:10.1038/s41598-019-43426-w. This article has 125 citations and is from a poor quality or predatory journal.

18. (freire2019humangutderivedorganoids pages 12-13): Rachel Freire, Laura Ingano, Gloria Serena, Murat Cetinbas, Anthony Anselmo, Anna Sapone, Ruslan I. Sadreyev, Alessio Fasano, and Stefania Senger. Human gut derived-organoids provide model to study gluten response and effects of microbiota-derived molecules in celiac disease. Scientific Reports, May 2019. URL: https://doi.org/10.1038/s41598-019-43426-w, doi:10.1038/s41598-019-43426-w. This article has 125 citations and is from a poor quality or predatory journal.

19. (hidray2023cytokinesinfluencegut pages 65-68): TY Hidray. Cytokines influence gut duodenal epithelial cells differentiation and celiac disease development. Unknown journal, 2023.

20. (piscaglia2014intestinalstemcells pages 10-11): Anna Chiara Piscaglia. Intestinal stem cells and celiac disease. World Journal of Stem Cells, 6:213, Jan 2014. URL: https://doi.org/10.4252/wjsc.v6.i2.213, doi:10.4252/wjsc.v6.i2.213. This article has 29 citations.

21. (piscaglia2014intestinalstemcells pages 5-7): Anna Chiara Piscaglia. Intestinal stem cells and celiac disease. World Journal of Stem Cells, 6:213, Jan 2014. URL: https://doi.org/10.4252/wjsc.v6.i2.213, doi:10.4252/wjsc.v6.i2.213. This article has 29 citations.

22. (voisine2021interplaybetweengluten pages 6-7): Jordan Voisine and Valérie Abadie. Interplay between gluten, hla, innate and adaptive immunity orchestrates the development of coeliac disease. Frontiers in Immunology, Jun 2021. URL: https://doi.org/10.3389/fimmu.2021.674313, doi:10.3389/fimmu.2021.674313. This article has 53 citations and is from a peer-reviewed journal.

---

Query 5: Given the following hypothesis (and rationale) about the pathogenesis of celiac disease, find scientific evidence to support and/or refute this hypothesis.
Format your response with the following headings: **Supporting evidence**: <supporting info>, **Countering evidence**: <refutation>, **Conclusion**: <conclusion>

Hypothesis: Hypothesis: : Microbial production of tissue transglutaminase-modifying enzymes alters autoantigen structure and immunogenicity, with specific bacterial strains either promoting or protecting against celiac disease through post-translational modifications.
Rationale: : Gut microbiota produce diverse enzymes that can modify host proteins. Bacterial enzymes could alter tissue transglutaminase structure, affecting its recognition by autoantibodies and T cells in celiac disease.
Answer 5: **Supporting evidence**:
The hypothesis posits that microbial enzymes can modify host tissue transglutaminase (tTG), altering its structure and immunogenicity, with specific strains promoting or protecting against celiac disease (CD) via these modifications. Several sources suggest this is plausible. Microbial transglutaminase (mTG), produced by gut microbiota and used in food processing, can functionally mimic tTG (lerner2020processedfoodadditive pages 3-5, torsten2018microbialtransglutaminaseis pages 2-3). It is hypothesized that mTG and possibly other microbial proteases could alter host tTG function and structure, thereby increasing its immunogenicity (lerner2015possibleassociationbetween pages 1-2, lerner2015possibleassociationbetween pages 2-4). Some research indicates that enzymes from "pathobionts" (specific bacterial strains) can influence tTG structure through cross-linking and deamidation, potentially altering its immunogenicity and promoting CD (lerner2020processedfoodadditive pages 1-3). Microbial enzymes, particularly mTG from various sources including bacteria and fungi, are suggested to modify host tTG, changing its structure and immune recognition (lerner2020processedfoodadditive pages 11-12, lerner2020processedfoodadditive pages 7-9, torsten2018microbialtransglutaminaseis pages 6-6). Specific microbial strains like *Streptococcus suis* produce transglutaminase enzymes that may participate in CD autoimmunogenesis by potentially modifying host tTG (torsten2018microbialtransglutaminaseis pages 1-2, torsten2018microbialtransglutaminaseis pages 2-3, torsten2018microbialtransglutaminaseis pages 6-6). Other microbes like *Streptomyces mobaraense*, *Streptoverticillium species*, *Streptomyces hygroscopicus*, *Saccharomyces cerevisiae*, and *Candida albicans* also produce transglutaminases that could potentially influence host tTG (torsten2018microbialtransglutaminaseis pages 1-2, lerner2015possibleassociationbetween pages 2-4, torsten2018microbialtransglutaminaseis pages 6-6). While direct evidence for mTG altering host tTG *in vivo* is noted as somewhat limited (lerner2015possibleassociationbetween pages 8-9), the potential for microbial enzymes to affect tTG's immunogenicity through cross-linking activities or other modifications is a recurring theme (lerner2020processedfoodadditive pages 3-5).

**Countering evidence**:
Several sources indicate limitations or alternative interpretations. Much of the research focuses on microbial enzymes, particularly mTG, modifying *gliadin* peptides rather than directly modifying host tTG (caminero2016duodenalbacteriafrom pages 19-23, torsten2018microbialtransglutaminaseis pages 2-3, lerner2016theindustrialfood pages 1-5). The immunogenic complexes often described are mTg-gliadin neo-epitopes (torsten2018microbialtransglutaminaseis pages 2-3, lerner2016theindustrialfood pages 1-5). One article explicitly states it does not present direct evidence addressing microbial modification of tTG itself (caminero2016duodenalbacteriafrom pages 19-23). There is reportedly no direct experimental evidence that specific bacteria or their products degrade modified tTG or prevent its pathogenic modification; observed benefits from probiotics are often attributed to gluten degradation before transglutaminase action or modulation of inflammation (chander2018crosstalkbetweengluten pages 8-9). Similarly, while synbiotics containing *Lactobacillus* and *Bifidobacterium* species can decrease anti-tTG antibody levels, the precise mechanisms, such as direct degradation of microbially modified tTG or prevention of pathogenic tTG modifications by these probiotics, are not fully elucidated, and direct degradation is not mentioned (demiroren2020canasynbiotic pages 6-7, demiroren2020canasynbiotic pages 4-6). Some literature emphasizes the central role of *host* tTG in CD pathogenesis and does not support a significant role for microbial modification of tTG as a primary factor (esposito2005tissuetransglutaminaseand pages 9-11, esposito2005tissuetransglutaminaseand pages 1-2, sabatino2012thefunctionof pages 4-5). Protective effects of certain bacteria, such as those expressing elafin or various probiotic strains, are often linked to the degradation of immunogenic gliadin peptides or modulation of host immune responses, rather than direct beneficial modification of tTG (sulic2015transglutaminaseasa pages 12-13, demiroren2020canasynbiotic pages 7-8, chander2018crosstalkbetweengluten pages 8-9). The primary pathogenic role of host tTG is well-established, and microbial contributions, while potentially complementary, may not supplant this (lerner2016theindustrialfood pages 1-5, lerner2020processedfoodadditive pages 1-3).

**Conclusion**:
The hypothesis that microbial enzymes alter host tTG structure and immunogenicity, with specific strains promoting or protecting against CD through such modifications, finds some support in the provided context, primarily through the suggested actions of microbial transglutaminases. Enzymes from microbes like *Streptococcus suis*, various *Streptomyces* species, and *Candida albicans* are implicated as potentially modifying host tTG (torsten2018microbialtransglutaminaseis pages 1-2, torsten2018microbialtransglutaminaseis pages 6-6, lerner2020processedfoodadditive pages 1-3). However, direct *in vivo* evidence for microbial modification of host tTG leading to altered autoantigenicity as a primary driver of CD is still developing and often described as limited or hypothetical (lerner2015possibleassociationbetween pages 8-9, caminero2016duodenalbacteriafrom pages 19-23). A significant portion of the literature emphasizes microbial modification of *gliadin* peptides by mTG, or mTG mimicking tTG's action on gliadin, rather than direct alteration of host tTG itself (torsten2018microbialtransglutaminaseis pages 2-3, lerner2016theindustrialfood pages 1-5). While some bacteria like *Lactobacillus* and *Bifidobacterium* species show protective effects in CD, the mechanisms described predominantly involve gluten degradation or immunomodulation, rather than direct beneficial post-translational modification of host tTG (chander2018crosstalkbetweengluten pages 8-9, demiroren2020canasynbiotic pages 6-7). The centrality of host tTG in deamidating gluten remains the dominant paradigm in CD pathogenesis (esposito2005tissuetransglutaminaseand pages 9-11, sabatino2012thefunctionof pages 4-5). Therefore, while microbial enzymes might contribute to the complexity of CD by potentially interacting with or modifying host tTG, their role as primary drivers of tTG autoantigenicity through direct modification, and the specific protective mechanisms via tTG modification, require more definitive scientific validation.
References 5:
1. (torsten2018microbialtransglutaminaseis pages 2-3): Matthias Torsten and Lerner Aaron. Microbial transglutaminase is immunogenic and potentially pathogenic in pediatric celiac disease. Frontiers in Pediatrics, Dec 2018. URL: https://doi.org/10.3389/fped.2018.00389, doi:10.3389/fped.2018.00389. This article has 44 citations and is from a peer-reviewed journal.

2. (caminero2016duodenalbacteriafrom pages 19-23): Alberto Caminero, Heather J. Galipeau, Justin L. McCarville, Chad W. Johnston, Steve P. Bernier, Amy K. Russell, Jennifer Jury, Alexandra R. Herran, Javier Casqueiro, Jason A. Tye-Din, Michael G. Surette, Nathan A. Magarvey, Detlef Schuppan, and Elena F. Verdu. Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology, 151:670-683, Oct 2016. URL: https://doi.org/10.1053/j.gastro.2016.06.041, doi:10.1053/j.gastro.2016.06.041. This article has 272 citations and is from a highest quality peer-reviewed journal.

3. (chander2018crosstalkbetweengluten pages 8-9): Atul Munish Chander, Hariom Yadav, Shalini Jain, Sanjay Kumar Bhadada, and Devinder Kumar Dhawan. Cross-talk between gluten, intestinal microbiota and intestinal mucosa in celiac disease: recent advances and basis of autoimmunity. Frontiers in Microbiology, Nov 2018. URL: https://doi.org/10.3389/fmicb.2018.02597, doi:10.3389/fmicb.2018.02597. This article has 91 citations and is from a peer-reviewed journal.

4. (demiroren2020canasynbiotic pages 6-7): Kaan Demiroren. Can a synbiotic supplementation contribute to decreasing anti-tissue transglutaminase levels in children with potential celiac disease? Pediatric Gastroenterology, Hepatology & Nutrition, 23:397-404, Jul 2020. URL: https://doi.org/10.5223/pghn.2020.23.4.397, doi:10.5223/pghn.2020.23.4.397. This article has 12 citations and is from a peer-reviewed journal.

5. (esposito2005tissuetransglutaminaseand pages 9-11): Carla Esposito, Ivana Caputo, Salvatore Auricchio, and Riccardo Troncone. Tissue transglutaminase and celiac disease. Progress in Experimental Tumor Research, pages 158-173, Jan 2005. URL: https://doi.org/10.1159/000084239, doi:10.1159/000084239. This article has 7 citations and is from a peer-reviewed journal.

6. (lerner2015possibleassociationbetween pages 1-2): Aaron Lerner and Torsten Matthias. Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutrition Reviews, 73:544-552, Jun 2015. URL: https://doi.org/10.1093/nutrit/nuv011, doi:10.1093/nutrit/nuv011. This article has 136 citations and is from a peer-reviewed journal.

7. (lerner2015possibleassociationbetween pages 8-9): Aaron Lerner and Torsten Matthias. Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutrition Reviews, 73:544-552, Jun 2015. URL: https://doi.org/10.1093/nutrit/nuv011, doi:10.1093/nutrit/nuv011. This article has 136 citations and is from a peer-reviewed journal.

8. (lerner2016theindustrialfood pages 1-5): T. Matthias, P. Jeremias, S. Neidhöfer, and Aaron Lerner. The industrial food additive, microbial transglutaminase, mimics tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmunity Reviews, 15:1111-1119, Dec 2016. URL: https://doi.org/10.1016/j.autrev.2016.09.011, doi:10.1016/j.autrev.2016.09.011. This article has 90 citations and is from a peer-reviewed journal.

9. (lerner2020processedfoodadditive pages 1-3): Aaron Lerner and Torsten Matthias. Processed food additive microbial transglutaminase and its cross-linked gliadin complexes are potential public health concerns in celiac disease. International Journal of Molecular Sciences, 21:1127, Feb 2020. URL: https://doi.org/10.3390/ijms21031127, doi:10.3390/ijms21031127. This article has 36 citations and is from a peer-reviewed journal.

10. (lerner2020processedfoodadditive pages 11-12): Aaron Lerner and Torsten Matthias. Processed food additive microbial transglutaminase and its cross-linked gliadin complexes are potential public health concerns in celiac disease. International Journal of Molecular Sciences, 21:1127, Feb 2020. URL: https://doi.org/10.3390/ijms21031127, doi:10.3390/ijms21031127. This article has 36 citations and is from a peer-reviewed journal.

11. (lerner2020processedfoodadditive pages 3-5): Aaron Lerner and Torsten Matthias. Processed food additive microbial transglutaminase and its cross-linked gliadin complexes are potential public health concerns in celiac disease. International Journal of Molecular Sciences, 21:1127, Feb 2020. URL: https://doi.org/10.3390/ijms21031127, doi:10.3390/ijms21031127. This article has 36 citations and is from a peer-reviewed journal.

12. (lerner2020processedfoodadditive pages 7-9): Aaron Lerner and Torsten Matthias. Processed food additive microbial transglutaminase and its cross-linked gliadin complexes are potential public health concerns in celiac disease. International Journal of Molecular Sciences, 21:1127, Feb 2020. URL: https://doi.org/10.3390/ijms21031127, doi:10.3390/ijms21031127. This article has 36 citations and is from a peer-reviewed journal.

13. (sabatino2012thefunctionof pages 4-5): Antonio Di Sabatino, Alessandro Vanoli, Paolo Giuffrida, Ombretta Luinetti, Enrico Solcia, and Gino Roberto Corazza. The function of tissue transglutaminase in celiac disease. Autoimmunity Reviews, 11:746-753, Aug 2012. URL: https://doi.org/10.1016/j.autrev.2012.01.007, doi:10.1016/j.autrev.2012.01.007. This article has 197 citations and is from a peer-reviewed journal.

14. (torsten2018microbialtransglutaminaseis pages 1-2): Matthias Torsten and Lerner Aaron. Microbial transglutaminase is immunogenic and potentially pathogenic in pediatric celiac disease. Frontiers in Pediatrics, Dec 2018. URL: https://doi.org/10.3389/fped.2018.00389, doi:10.3389/fped.2018.00389. This article has 44 citations and is from a peer-reviewed journal.

15. (torsten2018microbialtransglutaminaseis pages 6-6): Matthias Torsten and Lerner Aaron. Microbial transglutaminase is immunogenic and potentially pathogenic in pediatric celiac disease. Frontiers in Pediatrics, Dec 2018. URL: https://doi.org/10.3389/fped.2018.00389, doi:10.3389/fped.2018.00389. This article has 44 citations and is from a peer-reviewed journal.

16. (demiroren2020canasynbiotic pages 4-6): Kaan Demiroren. Can a synbiotic supplementation contribute to decreasing anti-tissue transglutaminase levels in children with potential celiac disease? Pediatric Gastroenterology, Hepatology & Nutrition, 23:397-404, Jul 2020. URL: https://doi.org/10.5223/pghn.2020.23.4.397, doi:10.5223/pghn.2020.23.4.397. This article has 12 citations and is from a peer-reviewed journal.

17. (demiroren2020canasynbiotic pages 7-8): Kaan Demiroren. Can a synbiotic supplementation contribute to decreasing anti-tissue transglutaminase levels in children with potential celiac disease? Pediatric Gastroenterology, Hepatology & Nutrition, 23:397-404, Jul 2020. URL: https://doi.org/10.5223/pghn.2020.23.4.397, doi:10.5223/pghn.2020.23.4.397. This article has 12 citations and is from a peer-reviewed journal.

18. (esposito2005tissuetransglutaminaseand pages 1-2): Carla Esposito, Ivana Caputo, Salvatore Auricchio, and Riccardo Troncone. Tissue transglutaminase and celiac disease. Progress in Experimental Tumor Research, pages 158-173, Jan 2005. URL: https://doi.org/10.1159/000084239, doi:10.1159/000084239. This article has 7 citations and is from a peer-reviewed journal.

19. (lerner2015possibleassociationbetween pages 2-4): Aaron Lerner and Torsten Matthias. Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutrition Reviews, 73:544-552, Jun 2015. URL: https://doi.org/10.1093/nutrit/nuv011, doi:10.1093/nutrit/nuv011. This article has 136 citations and is from a peer-reviewed journal.

20. (sulic2015transglutaminaseasa pages 12-13): Ana-Marija Sulic, Kalle Kurppa, Tiina Rauhavirta, Katri Kaukinen, and Katri Lindfors. Transglutaminase as a therapeutic target for celiac disease. Expert Opinion on Therapeutic Targets, 19:335-348, Feb 2015. URL: https://doi.org/10.1517/14728222.2014.985207, doi:10.1517/14728222.2014.985207. This article has 41 citations and is from a peer-reviewed journal.
